LeMaitre Vascular (NASDAQ:LMAT) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

LeMaitre Vascular (NASDAQ:LMAT) posted its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01, Zacks reports. The firm had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 23.13%.The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.49 earnings per share. LeMaitre Vascular updated its FY 2026 guidance to 2.810-3.010 EPS and its Q1 2026 guidance to 0.640-0.690 EPS.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Q4 2025 delivered strong operating performance with 16% sales growth, a 71.7% gross margin, operating income up 47% and Q4 EPS of $0.68 (+39%); FY2025 organic revenue grew 14% and free cash flow was $74.5M with $359M in cash and securities.
• Management guided 2026 to $280M revenue (organic +12%), a 72.1% gross margin, adjusted operating income of $77.8M (+21%) and EPS of $2.91 (+22% adjusted), signaling continued operating leverage.
• Commercial momentum from new products and international expansion — Autograft now approved in 52 countries with an expected ~<$10M> in international autograft sales for 2026 (driving ~$6M of growth), Artegraft outperformed in 2025 (~$4M) and management sees a larger TAM (now suggesting ~ $30M) with further RFA/RestoreFlow geographic rollouts planned.
• Shareholder returns increased — board approved a new $100M share repurchase program and raised the Q1 2026 dividend 25% to $0.25, the 15th consecutive annual raise.
• Operational headwinds and risks — transferring RestoreFlow manufacturing to Burlington and consolidating the Chicago RFA facility will raise 2026 CapEx to ~ $11M and may pressure near-term margins, and a January 2026 cyber incident is under review (company says impact is reflected in guidance but risk remains).

LeMaitre Vascular Stock Down 5.7%

Shares of NASDAQ LMAT traded down $6.47 during midday trading on Friday, reaching $107.22. 259,408 shares of the company’s stock were exchanged, compared to its average volume of 176,755. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $115.33. The business’s fifty day moving average price is $86.55 and its two-hundred day moving average price is $88.30. The stock has a market capitalization of $2.43 billion, a PE ratio of 42.83, a price-to-earnings-growth ratio of 2.03 and a beta of 0.72.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be paid a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, March 12th. LeMaitre Vascular’s payout ratio is 31.87%.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 beat and solid revenue growth — LMAT reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.), with revenue up ~15.7% year-over-year; the beat supports upside to expectations. Read More.
• Positive Sentiment: Raised guidance — management raised Q1 FY2026 EPS guidance to $0.64–$0.69 (vs. $0.62 consensus) and FY2026 EPS to $2.81–$3.01 (vs. ~2.61 consensus), and revenue guidance of $276M–$284M (above consensus). Strong guidance is a primary bullish driver. Read More.
• Positive Sentiment: Dividend increase — LMAT declared a quarterly dividend of $0.25 (25% raise from $0.20), signaling confidence in cash flow and returning capital to shareholders (ex-dividend March 12).
• Positive Sentiment: Analyst upgrades/target raises — several firms raised targets or maintained buy/outperform stances (Roth MKM reaffirmed buy and raised target to $117; Citizens JMP raised to $118), providing additional analyst support. Read More.
• Neutral Sentiment: Earnings call transcript and detail — the full transcript is available for investors who want deeper color on drivers (procedure volumes, product mix, buybacks, margin cadence). Read More.
• Negative Sentiment: Mixed analyst signals and some targets imply limited near-term upside — Wells Fargo kept an equal-weight rating and raised its target only to $94 (below current levels); Barrington raised its target to $105 but that implies little upside from recent prices. These divergent views can spur profit-taking. Read More.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LMAT shares. Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Citizens Jmp increased their price objective on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday. Wells Fargo & Company lifted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a report on Thursday. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Finally, Barrington Research raised their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $106.50.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in LeMaitre Vascular by 144.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock valued at $31,731,000 after purchasing an additional 231,157 shares during the last quarter. Millennium Management LLC grew its position in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the last quarter. First Trust Advisors LP grew its position in shares of LeMaitre Vascular by 13.4% during the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares during the last quarter. Geode Capital Management LLC raised its stake in LeMaitre Vascular by 20.1% during the fourth quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after acquiring an additional 105,921 shares during the period. Finally, Algert Global LLC lifted its holdings in LeMaitre Vascular by 356.3% in the third quarter. Algert Global LLC now owns 66,268 shares of the medical instruments supplier’s stock worth $5,799,000 after acquiring an additional 51,744 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.